Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Mel Evans / AP
Janssen, a drug company owned by Johnson & Johnson, published its first-ever "transparency report" Monday. It covers a wide range of topics, from pricing to clinical data, reflecting the growing pressure pharmaceutical companies face from patients and the public who are worried and angry about rising drug costs. Janssen said it raised list prices by 8.5% in 2016 and the net price increase, after $11 billion in rebates and discounts, was 3.5%.
The takeaway: There's a lot of P.R. material, naturally. But the report also reinforces the drug industry's main talking points right now: That others in the drug supply chain are getting sizable portions of drug price increases, and that net prices are below medical inflation. Janssen even mapped out a flow chart of how drugs get from them to consumers.
Yes, but: Drug companies still set the prices, and the fact that net price increases are below medical inflation masks the fact they are still outpacing broader economic inflation, which is why people are feeling the pinch in their wallets.